Global Viral Vector Production (Research-use) Market Research Report 2022 TO 2028

Viral vectors are increasingly being employed in ongoing clinical trials owing to their efficiency in gene delivery. Significant advancements in delivery vectors that have resulted in the increased therapeutic efficacy of such vectors for gene delivery are driving the market for viral vector production (research-use). Amongst all viral vectors, lentivirus, adeno-associated virus, and adenovirus are the most used vectors across research settings.

The global Viral Vector Production (Research-use) market size is projected to reach US$ 3654.6 million by 2028, from US$ 993 million in 2021, at a CAGR of 18.8% during 2022-2028.

VIEW FULL REPORT
https://reports.valuates.com/market-reports/QYRE-Auto-4C11915/global-viral-vector-production-research-use

the viral vector production market has been experiencing significant growth and interest due to the increasing use of viral vectors in gene therapy, vaccine development, and other biotechnological applications. Viral vectors are modified viruses that are used to deliver genetic material into cells, making them valuable tools in medical and research fields. While I don't have the most current data, here are some key factors that have been influencing the viral vector production market:

Gene Therapy Applications:

Gene therapy involves the introduction of genetic material into a patient's cells to treat or prevent genetic disorders, cancer, and other diseases.
Viral vectors, such as adeno-associated viruses (AAV) and lentiviruses, are commonly used to deliver therapeutic genes to target cells.
The growing interest in gene therapy as a potential cure for previously untreatable diseases has been a major driver for the viral vector production market.
Vaccine Development:

Viral vectors have also been utilized in vaccine development, particularly in the development of novel vaccines, including for emerging infectious diseases.
Vectors like adenoviruses have been used to deliver genetic material from pathogens, triggering an immune response and conferring immunity without causing the actual disease.
Research and Drug Discovery:

Viral vectors play a crucial role in basic research, drug discovery, and target validation in the pharmaceutical industry.
They are used to modify cells and study gene function, which can aid in understanding disease mechanisms and identifying potential therapeutic targets.
Advancements in Viral Vector Technologies:

Ongoing advancements in biotechnology, genetic engineering, and vector design have led to the development of safer and more efficient viral vectors.
New production methods and improved vector engineering have enhanced the scalability and yield of viral vector production.
Regulatory Environment:

The regulatory landscape for gene therapies and vaccines has been evolving, with regulatory agencies providing clearer guidelines and accelerated approval pathways for certain therapies.
This has encouraged investment in the viral vector production market and the development of new treatments.

GET FREE SAMPLE
https://reports.valuates.com/request/sample/QYRE-Auto-4C11915/Global_Viral_Vector_Production_Research_use_Market_Research_Report_2022

Segment by Type
Adeno-associated virus (AAV)
Lentivirus
Adenovirus
Retrovirus
Others

Segment by Application
Cell & Gene Therapy Development
Vaccine Development
Biopharmaceutical and Pharmaceutical Discovery
Biomedical Research

BY REGION
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

BY COMPANY
Merck KGaA
Lonza
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Cobra Biologics Ltd.
Thermo Fisher Scientific
Waisman Biomanufacturing
Genezen
YPOSKESI
Advanced BioScience Laboratories, Inc. (ABL, Inc.)
Novasep Holding S.A.S
Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
Vigene Biosciences, Inc.
General Electric Company (GE Healthcare)
CEVEC Pharmaceuticals GmbH
Batavia Biosciences B.V.
Biovion oy
Wuxi AppTec Co., Ltd.
VGXI, Inc.
Catalent Inc.
Miltenyi Biotec GmbH
SIRION Biotech GmbH
Virovek Incorporation
BioNTech IMFS GmbH
VIVEbiotech S.L.
Creative Biogene
Vibalogics GmbH
Takara Bio.
Cell and Gene Therapy Catapult
BlueBird Bio
Addgene, Inc.
Aldevron, L.L.C.
Audentes Therapeutics
BioMarin Pharmaceutical
RegenxBio, Inc.

SIMILAR REPORTS

https://reports.valuates.com/market-reports/QYRE-Auto-23M8886/global-viral-vector-and-plasmid-dna

https://reports.valuates.com/market-reports/QYRE-Auto-0F12107/global-viral-vector-development-service-sales

https://reports.valuates.com/market-reports/QYRE-Auto-29B11713/global-viral-vector-purification

https://reports.valuates.com/market-reports/QYRE-Auto-30G10233/global-and-united-states-viral-vector-vaccines

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Twitter - https://twitter.com/valuatesreports

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

This release was published on openPR.